Charles Schwab’s TriSalus Life Sciences TLSI Stock Holding History

Charles Schwab’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$491K	Buy	107,945 +23,808	+28%	+$94.6K	﹤0.01%	3238
2026 Q1	$337K	Sell	84,137 -15,940	-16%	-$78K	﹤0.01%	3218
2025 Q4	$699K	Buy	100,077 +42,772	+75%	+$240K	﹤0.01%	3049
2025 Q3	$266K	Buy	57,305 +7,293	+15%	+$34.1K	﹤0.01%	3317
2025 Q2	$273K	Buy	50,012 +40,012	+400%	+$215K	﹤0.01%	3337
2025 Q1	$55.2K	Buy	+10,000	New	+$53.2K	﹤0.01%	3395

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Charles Schwab's TLSI Position: Q2 2026 in Review

Charles Schwab increased its TriSalus Life Sciences (TLSI) stake by 28% in Q2 2026, buying an estimated $94.6K and bringing the position to 107,945 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

Charles Schwab first reported a position in TLSI in Q1 2025 and has held it in 6 quarters since. The position peaked at $699K in Q4 2025. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Charles Schwab held 107,945 shares of TriSalus Life Sciences worth $491K as of Q2 2026.
Charles Schwab bought 23,808 TriSalus Life Sciences shares in Q2 2026, an estimated $94.6K.
TriSalus Life Sciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3238 holding.
Charles Schwab first reported a position in TriSalus Life Sciences in Q1 2025 and has held it in 6 quarters since.
Charles Schwab's TriSalus Life Sciences position peaked at $699K in Q4 2025.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.